Biomolecular Structure and Mechanism, Structure-Based Drug Design
生物分子结构与机制、基于结构的药物设计
基本信息
- 批准号:7732999
- 负责人:
- 金额:$ 128.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:ATP phosphohydrolaseBindingBinding SitesBiological AssayBiological ModelsCatalytic DomainCellsChemistryCisplatinComplexDNA-Directed RNA PolymeraseDevelopmentDimerizationDouble-Stranded RNADrug DesignDrug Metabolic DetoxicationElementsEnzymesExhibitsFamilyFamily memberFutureGene ExpressionGeneral Transcription FactorsGenetic TranscriptionGlutathione S-TransferaseGlutathione Transferase muHumanHydrolysisIn VitroIonsIsoenzymesKineticsLengthLiverMalignant NeoplasmsMediatingModelingModificationNitric OxideNucleotidesObject AttachmentPersonal SatisfactionPlayProcessProdrugsPropertyProtein IsoformsProtein OverexpressionProteinsRNARNA InterferenceRNA ProcessingRNA polymerase sigma 70ReactionRecyclingReportingRibonuclease IIIRoleShapesSmall Interfering RNAStructureanticancer activityantimicrobial drugbasecancer cellcytotoxicdesignds-DNAendonucleaseenzyme mechanismhuman DICER1 proteinin vivomembernovelphosphodiesterprotein foldingresearch studystructural biologytranscription factor
项目摘要
RNA interference is mediated by small interfering RNAs produced by members of the ribonuclease III (RNase III) family, including Dicer. For mechanistic studies, bacterial RNase III has been a valuable model system for the entire family. Previously, we have shown how the dimerization of the endonuclease domain of the enzyme creates a catalytic valley where two catalytic sites are located, how the catalytic valley accommodates a dsRNA in a manner such that each of the two RNA strands is aligned with one of the two catalytic sites, how the hydrolysis of each strand involves both subunits (residues from one subunit are involved in the selection of the scissile bond, while those from the partner subunit are involved in the cleavage chemistry), and how RNase III uses the two catalytic sites to create the 2-nucleotide 3' overhangs in its products. Recently, we have demonstrated how Mg2+ is essential for the formation of a catalytically competent protein-RNA complex, how the use of two Mg2+ ions can drive the hydrolysis of each phosphodiester bond, and how conformational changes in both the substrate and the protein are critical elements for assembling the catalytic complex. Moreover, we have modeled a protein-substrate complex and a protein-reaction intermediate (transition state) complex in a meaningful way. Together, the models and crystal structures suggest a stepwise mechanism for the enzyme to execute the phosphoryl transfer reaction. The structural information of protein-dsRNA interactions and the mechanism of dsRNA processing by bacterial RNase III can be extrapolated to other family members, including eukaryotic Rnt1p, Drosha and Dicer. RapA, as abundant as sigma 70 in the cell, is an RNA polymerase (RNAP)-associated Swi2/Snf2 protein with ATPase activity. It stimulates RNAP recycling during transcription. Recently, we reported the first structure of RapA, which is also the first full-length structure for the entire Swi2/Snf2 family. RapA contains seven domains, two of which exhibit novel protein folds. Our model of RapA in complex with ATP and double-stranded (ds) DNA suggests that RapA may bind to and translocate on dsDNA. Our kinetic template-switching assay shows that RapA facilitates the release of sequestered RNAP from a posttranscrption/posttermination complex (PTC) for transcription reinitiation. Our in vitro competition experiment indicates that RapA binds to core RNAP only but is readily displaceable by sigma 70. RapA is likely another general transcription factor, the structure of which provides a framework for future studies of this bacterial Swi2/Snf2 protein and its important roles in RNAP recycling during transcription. Glutathione S-transferase (GST) is a superfamily of detoxification enzymes, represented by GST-alpha, GST-mu, GST-pi, etc. GST-alpha is the predominant isoform of GST in human liver, playing important roles for our well being. GST-pi is overexpressed in many forms of cancer, thus presenting an opportunity for selective targeting of cancer cells. Our structure-based design of prodrugs intended to release cytotoxic levels of nitric oxide in GST-pi-overexpressing cancer cells yielded PABA/NO, which exhibited anticancer activity both in vitro and in vivo with a potency similar to that of cisplatin. The design was based on GST structures at both ground state and transition state. The ground-state structures outlined the shape and property of the substrate-binding site in different isozymes, and the structural information at the transition-state provided guidance for structural modifications of the prodrug molecules. Two key alterations of a GST-alpha-selective compound led to the GST-pi-selective PABA/NO.RNA interference is mediated by small interfering RNAs produced by members of the ribonuclease III (RNase III) family, including Dicer. For mechanistic studies, bacterial RNase III has been a valuable model system for the entire family. Previously, we have shown how the dimerization of the endonuclease domain of the enzyme creates a catalytic valley where two catalytic sites are located, how the catalytic valley accommodates a dsRNA in a manner such that each of the two RNA strands is aligned with one of the two catalytic sites, how the hydrolysis of each strand involves both subunits (residues from one subunit are involved in the selection of the scissile bond, while those from the partner subunit are involved in the cleavage chemistry), and how RNase III uses the two catalytic sites to create the 2-nucleotide 3' overhangs in its products. Recently, we have demonstrated how Mg2+ is essential for the formation of a catalytically competent protein-RNA complex, how the use of two Mg2+ ions can drive the hydrolysis of each phosphodiester bond, and how conformational changes in both the substrate and the protein are critical elements for assembling the catalytic complex. Moreover, we have modeled a protein-substrate complex and a protein-reaction intermediate (transition state) complex in a meaningful way. Together, the models and crystal structures suggest a stepwise mechanism for the enzyme to execute the phosphoryl transfer reaction. The structural information of protein-dsRNA interactions and the mechanism of dsRNA processing by bacterial RNase III can be extrapolated to other family members, including eukaryotic Rnt1p, Drosha and Dicer. RapA, as abundant as sigma 70 in the cell, is an RNA polymerase (RNAP)-associated Swi2/Snf2 protein with ATPase activity. It stimulates RNAP recycling during transcription. Recently, we reported the first structure of RapA, which is also the first full-length structure for the entire Swi2/Snf2 family. RapA contains seven domains, two of which exhibit novel protein folds. Our model of RapA in complex with ATP and double-stranded (ds) DNA suggests that RapA may bind to and translocate on dsDNA. Our kinetic template-switching assay shows that RapA facilitates the release of sequestered RNAP from a posttranscrption/posttermination complex (PTC) for transcription reinitiation. Our in vitro competition experiment indicates that RapA binds to core RNAP only but is readily displaceable by sigma 70. RapA is likely another general transcription factor, the structure of which provides a framework for future studies of this bacterial Swi2/Snf2 protein and its important roles in RNAP recycling during transcription. Glutathione S-transferase (GST) is a superfamily of detoxification enzymes, represented by GST-alpha, GST-mu, GST-pi, etc. GST-alpha is the predominant isoform of GST in human liver, playing important roles for our well being. GST-pi is overexpressed in many forms of cancer, thus presenting an opportunity for selective targeting of cancer cells. Our structure-based design of prodrugs intended to release cytotoxic levels of nitric oxide in GST-pi-overexpressing cancer cells yielded PABA/NO, which exhibited anticancer activity both in vitro and in vivo with a potency similar to that of cisplatin. The design was based on GST structures at both ground state and transition state. The ground-state structures outlined the shape and property of the substrate-binding site in different isozymes, and the structural information at the transition-state provided guidance for structur [summary truncated at 7800 characters]
项目成果
期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Structure-Based Design of Anticancer Prodrug PABA/NO.
- DOI:10.2147/dddt.s3931
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Ji X;Pal A;Kalathur R;Hu X;Gu Y;Saavedra JE;Buzard GS;Srinivasan A;Keefer LK;Singh SV
- 通讯作者:Singh SV
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.
- DOI:10.1074/jbc.m600697200
- 发表时间:2006-06-09
- 期刊:
- 影响因子:0
- 作者:Prabakaran P;Gan J;Feng Y;Zhu Z;Choudhry V;Xiao X;Ji X;Dimitrov DS
- 通讯作者:Dimitrov DS
Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
通过具有交叉反应性的 HIV-1 中和抗体与含有独特基序的 CDR-H2 和 H3 来模拟 CD4。
- DOI:10.1016/j.jmb.2005.12.062
- 发表时间:2006
- 期刊:
- 影响因子:5.6
- 作者:Prabakaran,Ponraj;Gan,Jianhua;Wu,You-Qiang;Zhang,Mei-Yun;Dimitrov,DimiterS;Ji,Xinhua
- 通讯作者:Ji,Xinhua
The mechanism of RNase III action: how dicer dices.
RNase III 作用机制:切丁机如何切丁。
- DOI:10.1007/978-3-540-75157-1_5
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Ji,Xinhua
- 通讯作者:Ji,Xinhua
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XINHUA JI其他文献
XINHUA JI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XINHUA JI', 18)}}的其他基金
CRYSTAL STRUCT OF ERA GTPASE DEPENDENT CELL CYCLE REGULATOR W/ RNA BINDING MOTIF
具有 RNA 结合基序的 ERA GTPase 依赖性细胞周期调节剂的晶体结构
- 批准号:
6205774 - 财政年份:1999
- 资助金额:
$ 128.6万 - 项目类别:
SYNCHROTRON CRYSTALLOGRAPHY OF GTPASES & GUANYLATE KINASES
GTP酶的同步加速器晶体学
- 批准号:
6120419 - 财政年份:1998
- 资助金额:
$ 128.6万 - 项目类别:
SYNCHROTRON CRYSTALLOG OF 7,8 DIHYDRO 6 HYDROXYMETHYLPTERIN PYROPHOSPHOKINASE
7,8 二氢 6 羟甲基蝶呤焦磷酸激酶的同步加速器晶体
- 批准号:
6120420 - 财政年份:1998
- 资助金额:
$ 128.6万 - 项目类别:
Structural Chemistry of Biomolecular Systems and Structu
生物分子系统和结构的结构化学
- 批准号:
7338457 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
Biomolecular Structure and Mechanism, Structure-Based Drug Design
生物分子结构与机制、基于结构的药物设计
- 批准号:
7592663 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
Biomolecular Structure and Mechanism, Structure-Based Drug Design
生物分子结构与机制、基于结构的药物设计
- 批准号:
8175306 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
Biomolecular Structure and Mechanism, Structure-Based Drug Design
生物分子结构与机制、基于结构的药物设计
- 批准号:
10702336 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
Structural of Biomolecular Systems by X Ray Diffraction
通过 X 射线衍射分析生物分子系统的结构
- 批准号:
6559206 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
Biomolecular Structure and Mechanism, Structure-Based Drug Design
生物分子结构与机制、基于结构的药物设计
- 批准号:
7965248 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
Biomolecular Structure and Mechanism, Structure-Based Drug Design
生物分子结构与机制、基于结构的药物设计
- 批准号:
10926000 - 财政年份:
- 资助金额:
$ 128.6万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Bridging the Gap: Next-Gen Tools for Accurate Prediction of Disordered Protein Binding Sites
弥合差距:准确预测无序蛋白质结合位点的下一代工具
- 批准号:
24K15172 - 财政年份:2024
- 资助金额:
$ 128.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design of protein crystal templates with multiple binding sites for tracking metal complex reactions.
设计具有多个结合位点的蛋白质晶体模板,用于跟踪金属络合物反应。
- 批准号:
23K04928 - 财政年份:2023
- 资助金额:
$ 128.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Dynamic changes in PIP2 binding sites and their impact on axonal targeting and function of epilepsy-associated KCNQ/Kv7 channels
PIP2 结合位点的动态变化及其对癫痫相关 KCNQ/Kv7 通道的轴突靶向和功能的影响
- 批准号:
10744934 - 财政年份:2023
- 资助金额:
$ 128.6万 - 项目类别:
Computational methods to identify small molecule RNA binding sites
识别小分子 RNA 结合位点的计算方法
- 批准号:
573688-2022 - 财政年份:2022
- 资助金额:
$ 128.6万 - 项目类别:
University Undergraduate Student Research Awards
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
- 批准号:
10704557 - 财政年份:2022
- 资助金额:
$ 128.6万 - 项目类别:
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
- 批准号:
10537846 - 财政年份:2022
- 资助金额:
$ 128.6万 - 项目类别:
Identifying new types of inhibitors in quinone binding sites in photosynthetic enzymes
鉴定光合酶醌结合位点的新型抑制剂
- 批准号:
2753921 - 财政年份:2022
- 资助金额:
$ 128.6万 - 项目类别:
Studentship
Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
开发针对不同冠状病毒受体结合位点的广泛纳米疫苗
- 批准号:
10328140 - 财政年份:2022
- 资助金额:
$ 128.6万 - 项目类别:
Exploiting Water Network Perturbations in Protein Binding Sites
利用蛋白质结合位点的水网络扰动
- 批准号:
10621368 - 财政年份:2021
- 资助金额:
$ 128.6万 - 项目类别:
SBIR Phase I: Nonlinear optical method for identifying protein-ligand binding sites
SBIR 第一阶段:识别蛋白质-配体结合位点的非线性光学方法
- 批准号:
2111821 - 财政年份:2021
- 资助金额:
$ 128.6万 - 项目类别:
Standard Grant